Under the treatment of the GLS1 selective inhibitor bis–2–(5–phenylacetamido–1,3,4–thiadiazol–2–yl)ethyl sulfide (BPTES), it was shown that a reduced glutamine consumption and HNSCC growth was detected, highlighting the significance of glutaminolysis in controlling the HNSCC malignancy [142]. The gene discussed is GLS; the disease is head and neck squamous cell carcinoma.